Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11311824 | 1.00 | CA2 (0.59) | CA2CA1MAPTZDHHC7ABCB1 | |
| SCHEMBL7948589 | 1.00 | CA2 (0.59) | CA2CA1MAPTZDHHC7ABCB1 | |
| SCHEMBL11537488 | 0.94 | MAPT (0.59) | CA2CA1MAPTZDHHC7ABCB1 | |
| SCHEMBL11864360 | 0.92 | MAPT (0.62) | CA2CA1MAPTZDHHC7ABCB1 | |
| SCHEMBL1667140 | 0.92 | MAPT (0.62) | CA2CA1MAPTZDHHC7ABCB1 | |
| SCHEMBL11534187 | 0.92 | MAPT (0.62) | CA2CA1MAPTZDHHC7ABCB1 | |
| SCHEMBL15939807 | 0.92 | MAPT (0.62) | CA2CA1MAPTZDHHC7ABCB1 | |
| SCHEMBL5749106 | 0.84 | MAPT (0.52) | CA2CA1MAPTZDHHC7TSHR | |
| SCHEMBL7095852 | 0.83 | CA1 (0.50) | CA2CA1MAPTZDHHC7ABCB1 | |
| SCHEMBL7096850 | 0.83 | MAPT (0.50) | CA2CA1MAPTZDHHC7TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190012-A1 | C-HALOGEN BOND FORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-06-18 | — | — | US | claimed |
| US-20140227184-A1 | C-HALOGEN BOND FORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2014-08-14 | — | — | US | claimed |
| CN-110800150-B | Non-aqueous electrolyte and electrolytic solution containing electrolyte stabilizing material, secondary battery containing the same, and use thereof | 株式会社村田制作所 | 2022-11-29 | — | — | CN | disclosed |
| CN-110800150-A | Non-aqueous electrolyte and electrolytic solution containing electrolyte stabilizing material, secondary battery containing the same, and use thereof | 株式会社村田制作所 | 2020-02-14 | — | — | CN | disclosed |
| US-6265440-B1 | STOMACH ULCERS | R-TECH UENO, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-5886034-A | ANTIULCER AGENTS | KABUSHIKI KAISHA UENO SEIYAKU KENKYUJO (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5770759-A | 13,14-DIHYDRO-15-KETO-PGF'S; VASOPRESSORS | R-TECH UENO, LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5591887-A | 13,14-DIHYDRO-15-KETO-PGFS | R-TECH UENO, LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| US-5428062-A | Side effect reduction | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1995-06-27 | — | — | US | disclosed |
| US-5380709-A | Prostaglandins E and anti ulcers containing same | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1995-01-10 | — | — | US | disclosed |
| US-5284858-A | Prostaglandins E and anti ulcers containing same | KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0284180-A1 | Prostaglandins E and anti ulcers containing same | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1988-09-28 | — | — | EP | disclosed |
| US-4256911-A | TRIFLUOROMETHYL-CARBOXY ESTERS | HOFFMANN-LA ROCHE INC. (US) | 1981-03-17 | — | — | US | disclosed |
| US-4211724-A | ENANTIOMORPHS, INTERMEDIATE AMIDES WITH ASSYMETRIC CARBON ATOM | HOFFMAN-LA ROCHE INC. (US) | 1980-07-08 | — | — | US | disclosed |
| US-4138577-A | 11-Deoxy-cis-4,5-didehydro-ω-aryl-PGF compounds | THE UPJOHN COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4138575-A | 11-Deoxy-16-phenoxy-PGF compounds | THE UPJOHN COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4138573-A | 11-Deoxy-2,2-difluoro-ω-aryl-PGE compounds | THE UPJOHN COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4138576-A | 11-Deoxy-2,2-difluoro-ω-aryl-PGF compounds | THE UPJOHN COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4126754-A | 11-Deoxy-cis-4,5-didehydro-ω-aryl-PGE compounds | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-3933889-A | 4,5-Cis-didehydro-PGF1.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190012-A1 | C-HALOGEN BOND FORMATION | CBR3, FOS, CBR1 | CA2 1303/4885CA1 429/4885MAPT 4035/4885 |
| US-20140227184-A1 | C-HALOGEN BOND FORMATION | CBR3, FOS, CBR1 | CA2 1303/4885CA1 429/4885MAPT 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.